Is pemetinib (pemetinib) currently officially on the market in China?

Pemigatinib (Pemigatinib) has been officially launched in China, mainly entering the domestic market in the form of pemigatinib tablets. The drug is a targeted therapy drug, mainly used to treat indications such as advanced cholangiocarcinoma carrying FGFR gene fusion or rearrangement. Although it is already on the market, pemetinib has not yet been included in the domestic medical insurance catalog, so patients need to bear the full cost of the drug when purchasing it.

In the domestic market, pemetinib mainly comes in two specifications: 4.5mg 14 tablets and 9mg 14 tablets, with prices ranging from 2 to 5 RMB per box. Due to the high price, patients need to make reasonable arrangements for medication according to the doctor's recommendations when using it, and pay close attention to the treatment effects and possible adverse reactions. The purchasing channels are mainly through regular hospitals and authorized pharmacies to ensure the quality and safety of the drugs.

In comparison, the price of pemetinib in overseas markets is higher. Taking 13.5mg 14 tablets as an example, the price per box may exceed 7 RMB, and the price is greatly affected by exchange rate fluctuations. In addition, there are generic versions of pemetinib in overseas markets, and their prices are significantly lower than those of the original drug. For example, the price of pemetinib in 4.5 mg 14 tablets produced by Lucius Pharmaceuticals in Laos is about more than 700 yuan per box, which greatly reduces the patient's medication burden.

Overall, the launch of pemetinib in China has brought new treatment options to relevant patients, but since it has not yet been included in medical insurance, the economic pressure is still high. Patients should fully consider their own conditions when choosing medications, give priority to purchasing through formal channels, and consider overseas generic drugs as a supplementary solution based on specific needs and conditions. In the future, with the improvement of medical insurance policies, the accessibility of pemetinib is expected to further improve.

Reference materials:https://go.drugbank.com/drugs/DB15102